Drug Profile
PRN 1371
Alternative Names: PRN-1371Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Principia Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Solid tumours; Urogenital cancer
Most Recent Events
- 28 Sep 2020 Principia Biopharma has been acquired by Sanofi
- 19 Aug 2020 Principia Biopharma terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) and Urogenital cancer (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Spain and USA (PO) to focus company portfolio on immune-mediated diseases (NCT02608125)
- 01 Jan 2020 Suspended - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Spain, USA (PO)